# Cracking the FDA Code: 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →), PMA, and Drug Approval Routes
A blood pressure cuff and a heart valve implant both pass through the U.S. Food and Drug Administration (FDA). One requires a few hundred pages of paperwork proving it works like a device already on the market. The other can demand years of clinical trials and tens of thousands of pages of data. Same agency, wildly different scrutiny.
That gap is not bureaucratic randomness. It is the core logic of medical regulation: the higher the risk to a patient, the more evidence you must bring. Understand that one principle and the alphabet soup of FDA pathways suddenly makes sense.
The FDA sorts medical devices into three classes based on how much harm they could cause if they fail.
The class determines the pathway. The pathway determines the cost, timeline, and evidence burden. A founder who misjudges their device class can be off by years and millions of dollars.
The 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →) (named after a section of the U.S. Food, Drug, and Cosmetic Act) is a clearance, not an approval. The distinction matters. To get cleared, you do not prove your device is safe and effective from scratch. You prove it is substantially equivalent to a device already legally on the market, called a predicate device.
Think of it as regulatory inheritance. If a legally marketed catheter already exists and yours has the same intended use and similar technological characteristics, you argue: "Mine is basically that one." The FDA reviews the comparison and, if convinced, clears it.
Say a company builds a new digital thermometer. Thousands of cleared thermometers already exist. The company identifies a predicate, shows the same measurement principle, same intended use, and comparable accuracy testing. No large human trial required. Clearance often arrives in months, not years.
This is why 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →) dominates in volume. The vast majority of devices reaching the U.S. market do so through this route. It is faster and cheaper precisely because someone already carried the safety burden for the predicate.
The catch: 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →) devices can inherit the weaknesses of old predicates too. Critics argue that "substantial equivalence" can chain new devices to decades-old technology without fresh safety data. The FDA has tightened expectations over time, but the tension remains.
You can search cleared devices yourself in the FDA's free 510(k) database. Type in a product type and see the actual clearances, predicates, and dates.
Premarket Approval is the FDA's most demanding pathway, reserved for Class III devices that support or sustain life, or present significant injury risk. Here you cannot lean on a predicate. You must independently demonstrate safety and effectiveness, almost always through clinical trials.
A novel implantable heart valve has no true equivalent. The manufacturer runs clinical studies enrolling patients, tracks outcomes over years, and submits the full dataset. FDA reviewers scrutinize manufacturing, bench testing, and trial results. An advisory committee of outside experts may weigh in publicly. Approval can take years and cost dramatically more than a 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →).
The payoff for the company is a stronger competitive moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.Voir la définition complète →: a PMA device is harder for rivals to copy quickly, because they face the same steep evidence requirement.
Not every low-to-moderate risk device has a predicate. A genuinely novel but not high-risk product (many first-of-their-kind software diagnostics, for instance) can use the De Novo pathway. It creates a new device classification, which can then serve as a predicate for future 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →) submissions. It is lighter than PMA but still requires real evidence.
🎬 [VIDEO: "How the FDA Approves Medical Devices" — youtube.com — a clear plain-language walkthrough of device classes and pathways]
Devices and drugs are regulated by different parts of the FDA under different laws. Drugs (small-molecule pills, biologics such as antibodies) do not use 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →) or PMA at all.
The typical drug journey:
1. Preclinical testing: lab and animal studies.
2. Investigational New Drug (IND) application: permission to test in humans.
3. Clinical trials in three phases:
4. New Drug Application (NDA) for conventional drugs, or Biologics License Application (BLA) for biologics.
Attrition is brutal. Most compounds that enter human testing never reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.Voir la définition complète → market. Industry estimates for the full journey run into the hundreds of millions to well over a billion dollars per approved drug, though figures are widely debated and depend heavily on how failures are counted. Treat any single number as an estimate.
The FDA also runs expedited programs (Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review) to speed drugs for serious conditions with unmet need. These change the *speed* and *evidence sequencing*, not the fundamental requirement to show benefit.
Vérification des acquis
1. What is the central principle that determines how much scrutiny a medical device receives from the FDA?
2. A startup develops a new powered infusion pump similar to ones already on the market. Which pathway would this device most likely follow?
3. Why is a 510(k) described as a 'clearance' rather than an 'approval'?
4. Select ALL correct answers about the consequences of misjudging a device's risk class.
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers about what a manufacturer must demonstrate to obtain a 510(k) clearance using a predicate device.
Sélectionnez toutes les réponses correctes.
If you sell in Europe, the FDA is irrelevant. The European Union uses a different system, and the differences are structural, not cosmetic.
A device sold in the EU carries a CE mark, indicating it meets EU requirements. The pivotal contrast:
Historically, some devices reached the European market faster than the U.S. market because the CE process was less centralized. That reputation has shifted. The MDR, which replaced the older directives, raised evidence and post-market surveillance requirements significantly. Many companies now report longer timelines and Notified Body capacity bottlenecks under MDR.
A device cleared via 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →) in the U.S. is not automatically CE marked, and vice versa. Different classifications, different evidence expectations, different bodies. A go-to-marketgo-to-marketThe strategy defining how you'll launch a product: target segments, channels, value proposition and coordinated action plan.Voir la définition complète → plan must account for each jurisdiction separately. Companies often sequence launches: one region first, then adapt the dossier for the other.
The European Commission maintains free overview materials on the EU Medical Device Regulation if you want the primary-source framing.
You do not need to write submissions to use this fluency. You need to read the signals.
These labels are not marketing decoration. They tell you where a product sits on the risk-and-evidence spectrum, which directly shapes timelines, costs, and how defensible the business is.
This lesson is educational and not legal, medical, or investment advice.